新西兰细胞健康品牌MitoQ发布首个大型中国消费者临床试验成果

Core Insights - MitoQ has officially released mid-term data results from its clinical trial of MitoQ® Mitoquinol for Chinese consumers at the China International Import Expo, marking a significant milestone in its market entry in China [1][4] Clinical Trial Results - The clinical trial, conducted in collaboration with Zhejiang University, involved 140 participants over a 3-month period using a randomized controlled design [3] - Key findings include: - Improvement in alanine aminotransferase (ALT) levels, with reductions 1.5 times greater than the control group [3] - 65% of users reported significant energy improvement, with effects 1.5 times that of the control group [3] - 61% of users experienced reduced perceived stress, with results 1.8 times better than the control group [3] - 71% of users reported enhanced overall quality of life, with improvements in sleep, mood, or social interactions 2.3 times that of the control group [3] - Safety and tolerability were confirmed, with 85.7% of participants completing follow-up without adverse reactions [3] Strategic Collaborations - MitoQ signed a strategic cooperation agreement with Zhejiang University in 2023 to enhance cell health research [3] - The release of mid-term results is seen as a product of deepening collaboration with Chinese research institutions, providing authoritative data for global anti-aging technology [4][6] Market Positioning and Future Plans - MitoQ has been focusing on mitochondrial health for over 30 years and aims to strengthen its presence in the Chinese market [8] - The company has launched several initiatives in 2023, including a white paper on cellular anti-aging and new product releases to expand its product matrix [8] - MitoQ plans to continue driving innovation and research collaboration to support a "longevity economy" in China, addressing public health needs related to aging [12]